Stay updated with breaking news from Bryan Chow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations.
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations. However, many patients do not respond to immunotherapy.
Yale researchers have found that a mechanism for faulty DNA repair in tumors is a key factor in determining whether patients respond to immunotherapy.
Mastering automation to accelerate business transformation within healthcare organizations.